General Information of Drug (ID: DMS4IBW)

Drug Name
DS-1442 Drug Info
Indication
Disease Entry ICD 11 Status REF
Dyslipidemia 5C80-5C81 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
260936
CAS Number
CAS 27810-64-6
TTD Drug ID
DMS4IBW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Evacetrapib DMCDZ15 Cardiovascular disease BA00-BE2Z Phase 3 [3]
Dalcetrapib DMKNCVM Acute coronary syndrome BA41 Phase 3 [4]
Anacetrapib DMP2BFG Arteriosclerosis BD40 Phase 3 [5]
JTT-302 DMGLVBI Lipid metabolism disorder 5C52.Z Phase 2 [3]
DRL-17822 DMGD3XT Arteriosclerosis BD40 Phase 2 [3]
TA-8995 DMAZHT0 Cardiovascular disease BA00-BE2Z Phase 2 [6]
BAY-60-5521 DMXIDWE Arteriosclerosis BD40 Phase 1 [7]
Torcetrapib DMDHYM7 Hyperlipidaemia 5C80 Discontinued in Phase 2 [8]
CETi-1 DMUG5OB Arteriosclerosis BD40 Discontinued in Phase 2 [9]
CP-800569 DMZ0YU7 Arteriosclerosis BD40 Discontinued in Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholesteryl ester transfer protein (CETP) TTFQAYR CETP_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036983)
2 Ds-1442b is a Novel, Potent Cetp Inhibitor That Reduces Atherosclerosis by Hdl Elevation and Non-hdl Reduction. Circulation. 2012; 126: A11806.
3 The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
4 Clinical pipeline report, company report or official report of Roche (2009).
5 Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6.
6 Amgen To Acquire Privately-Held Dezima Pharma
7 Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8.
8 Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91.
9 CETi-1. AVANT. Curr Opin Investig Drugs. 2004 Mar;5(3):334-8.
10 Pfizer. Product Development Pipeline. March 31 2009.